Communiqués Recordati

Actions

REC

IT0003828271

Produits pharmaceutiques

Temps réel Borsa Italiana Autres places de cotation 11:41:09 16/06/2026			Varia. 5j.	Varia. 1 janv.
50,80 ^EUR	+0,30%		-0,29%	+4,66%

28/05	Italie - Les facteurs à suivre le 28 mai	RE
26/05	Le MIB sous pression ; les regards tournés vers Ormuz	AN

Communiqués

14/05	Recordati : First Quarter Report 2026	PU
12/05	RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2026 NET REVENUE +4.9%, EBITDA(1) +5.0%, ADJUSTED NET INCOME(2) +7.2%	GL
30/04	RECORDATI: SUMMARY REPORT OF THE VOTES – ORDINARY AND EXTRAORDINARY GENERAL MEETING OF THE SHAREHOLDERS 29.04.2026	PU
30/04	Recordati : 30th April 2026 - Summary report of the votes	PU
01/04	Recordati : 1st April 2026 - Report of the Board of Statutory Auditors to the Shareholders’ Meeting	PU
01/04	Recordati : 1 April 2026 - Financial Statements of Recordati S.p.A. at 31 December 2025 and related Report of the Auditing Firm	PU
27/03	RECORDATI: PUBLICATION OF DOCUMENTS RELATING TO THE ORDINARY AND EXTRAORDINARY GENERAL MEETING OF THE SHAREHOLDERS CALLED FOR 29.04.2026	PU
27/03	Recordati : 27 March 2026 - Directors' Report on item 1 on the agenda of the Shareholders’ Meeting 29.04.2026 (extraordinary session) – Delegation of authority to the BoDs pursuant to artt 2420-ter and 2443 of the Italian Civil Code	PU
27/03	Recordati : 27 March 2026 - Directors' Report on item 5 on the agenda (ordinary session) - Authorization to the purchase and disposal of treasury stock	PU
27/03	Recordati : 27 March 2026 - Directors' Report on item 4 on the agenda (ordinary session) - Approval of the “2026-2028 Performance Shares Plan”	PU
27/03	Recordati : 27 March 2026 - Directors' Report on item 3 on the agenda (ordinary session) - Report on the remuneration policy and the remuneration paid	PU
20/03	Recordati : 20th March 2026 - Call to an Ordinary and Extraordinary General Meeting of the Shareholders 29.04.2026	PU
20/03	Recordati : 20th March 2026 - Directors' Report on item 2 on the agenda (ordinary session) – Appointment of the Board of Statutory Auditors	PU
17/02	RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%	GL
17/02	RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE 11.8%, EBITDA 14.5%, ADJUSTED NET INCOME 14.5%	PU
29/01	RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA	GL
14/01	Recordati : 14 January 2026 - J.P. Morgan Healthcare Conference Presentation	PU
14/11	Recordati : First nine months 2025	PU
11/11	RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION	GL
11/11	Recordati : Directors' report on the distribution of an interim dividend and interim financial statements at 30 June 2025	PU
23/10/25	RECORDATI APPOINTS MIKE MCCLELLAN AS NEW CHIEF FINANCIAL OFFICER	GL
21/10/25	Recordati Launches 12th Edition of Arrigo Recordati Prize to Support Research in Paediatric Oncology	GL
31/07/25	RECORDATI: PUBLICATION OF THE MINUTES OF THE BOARD OF DIRECTORS’ MEETING HELD ON 29 JULY 2025	PU
31/07/25	Recordati : First Half 2025	PU
31/07/25	RECORDATI: PUBLICATION OF THE INTERIM REPORT FIRST HALF (AS AT 30.06.2025)	PU